Item 8.01. Other Information.
On January 9, 2020, Prevail Therapeutics Inc. issued a press release announcing
that it has granted a compassionate use request for the administration of PR001
to a single patient with Type 2 Gaucher disease, and separately that the Company
is proceeding with its Phase 1/2 clinical trial for the treatment of
neuronopathic Gaucher disease and expects to initiate patient dosing during the
first half of 2020.
A copy of this press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release dated January 9, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses